A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib
- 14 January 2022
- journal article
- research article
- Published by S. Karger AG in Pathobiology
- Vol. 89 (3) , 178-185
Abstract
Herein, we present a rare case of a nine-month-old boy diagnosed with infant-type hemispheric glioma (gliosarcoma subtype) at the left frontal lobe. Following subtotal resection, the patient started chemotherapy with the BABY POG protocol. We describe the clinical diagnosis, histological characteristics, radiological features, molecular aspects, and management of this tumor. A comprehensive molecular analysis on the tumor tissue showed a TPR-NTRK1 gene fusion. The patient was treated with a TRK inhibitor, larotrectinib, and exhibited a stable disease with residual lesion following 8 months of target therapy. The present study is the first report of an infantile gliosarcoma harboring NTRK1 rearrangement treated with larotrectinib.Keywords
This publication has 6 references indexed in Scilit:
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryNeuro-Oncology, 2021
- Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literatureBMC Pediatrics, 2021
- From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision ParadigmTrends in Cancer, 2021
- Late effects of pediatric brain tumorsCurrent Opinion in Pediatrics, 2019
- Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical ManagementJournal of Clinical Oncology, 2017
- Genetic Profile of GliosarcomasThe American Journal of Pathology, 2000